Cerebral small vessel disease is one of the most important causes of strokes and dementia. For the hypertensive or amyloidogenic variants, i.e. based on high blood pressure or pathological protein deposits, underlying risk factors, progression rates, prevention and therapy are different. This project aims to establish precise classification systems of these variants for clinical practice based on new imaging markers, e.g. for vascular wall integrity, inflammation and neuronal networks. In parallel, we will analyse new blood biomarkers for cerebral small vessel disease in a corresponding mouse model, integrate them into the classification scheme and apply them to patients.

Here you can find further information.